When it comes to mid-cap and small-cap biotech stocks, there are two ways shareholders get rewarded ahead of or after big drug development news. One is that the company grows and grows into its own monster, and the other way to rewards is that the company gets acquired by a large pharmaceutical or biotech company.
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться